Rituximab can deplete B-cells; in kidney transplantation as induction or desensitization. Since as I know regulatory B-lymphocyte  (BREG) phenotypes help prevent the rejection? (Please correct me if I am wrong.)Therefore, can RTX cause rejection worse instead of helping in the setting of acute cellular rejection? 

Thank you very much!

Similar questions and discussions